[Why it is necessary to reduce heart rate in the treatment of stable angina?].
The article is devoted to the role of heart rate (HR) as a risk factor of cardiovascular morbidity and mortality in patients with stable angina. It includes data from epidemiological surveys showing the value of elevated HR as a risk factor in many cardiovascular diseases. HR reducing therapy as one of cornerstone principles of stable angina treatment has been recently reinforced by the innovative medicine--selective and specific I(f) current inhibitor ivabradine (Coraxan). Results of a clinical development program demonstrated high anti-ischemic and antianginal efficacy of Coraxan in treatment of patients with stable angina.
Makolkin
V I
VI
Ziabrev
F N
FN
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology*; D006801:Humans
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers